Cell-based Hyper-interleukin 6 or Hyper-interleukin 11 secreting vaccines combined with low dose @entity786 in an orthotopic XXXX @entity263 model.

@entity263 @entity19 @entity5 @entity786 @entity57023 @entity14913 @entity320 @entity703
BACKGROUND: Cell based vaccines encoding @entity57023 ( @entity57023 ) and Hyper-IL-11 (H11) present high activity in @entity19 @entity320 and @entity703 model. We evaluated the efficacy of cellular vaccines modified with @entity57023 or H11 combined with @entity786 in orthotopic @entity19 @entity263 model. MATERIAL AND METHODS: @entity14913 cells were transduced with @entity57023 and H11 cDNA ( @entity14913 - @entity57023 and @entity14913 -H11). An orthotopic @entity14913 model based on the implantation of @entity14913 cells into the dorsolateral lobe of the prostate of C57BL6/J @entity19 was employed. The efficacy of @entity14913 - @entity57023 and @entity14913 -H11 vaccines evaluated in the therapeutic setting was compared with the @entity14913 cells modified with a mock transduced E1-deleted adenoviral vector ( @entity14913 -AdV) and non-modified irradiated @entity14913 cells ( @entity14913 IRR) in relation to naive (non-immunized) @entity19 . In the next experimental groups @entity19 vaccinated with @entity14913 - @entity57023 and @entity14913 -H11 received @entity786 (CY). Detection of immune cells in the spleen in @entity19 receiving vaccines combined with CY was evaluated. RESULTS: Modification of @entity14913 cells with @entity57023 increased the efficacy of @entity14913 -based whole-cell vaccine. The highest response rate was observed in @entity19 receiving @entity14913 - @entity57023 alone and combined with CY. Vaccination with @entity14913 - @entity57023 alone and combined with CY and @entity14913 H11 combined with CY extended median OS of @entity19 bearing orthotopic @entity14913 @entity5 in therapeutic setting. Low dose CY administered alone demonstrated some antitumor activity in employed model. @entity14913 - @entity57023 or @entity14913 -H11 combined with CY strongly augmented generation of CD8+, CD4+ T lymphocytes and memory T cells. Immunization with @entity14913 combined with or without CY suppressed generation of T regulatory cells. CONSLUSIONS: @entity263 vaccines modified with @entity57023 or H11 induce prostate @entity5 regression and increase @entity19 survival by stimulating the immune system. @entity786 added to modified @entity14913 vaccines demonstrated clinical benefit of treated @entity19 and enhanced anti- @entity5 immune response.
